Also, anti-HER2 antibodies are starting to emerge as a tool for gastric cancer treatment [37] and therefore, given the ability of HER2 cancer status to predict response to treatment, correlation between 18F-FDG uptake and receptor expression has been researched through the years. This evidence concerns the gene ERBB2 and gastric cancer.